The FDA's Assessment of Two Drugs for Chronic Weight Management â NEJM
11/09/2012
The FDA's Assessment of Two Drugs for Chronic Weight Management â NEJM.
- Listen to the podcast above - it's amazingly interesting
- Qsymia is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese) (1) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia
You should always consult with your physician before introducing any changes to your diet or level of physical activity.
Indication
Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
- 30 kg/m2 or greater (obese) or
- 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol
NEJM - http://www.nejm.org/doi/full/10.1056/NEJMp1211277?query=featured_home
Posted at 08:00 AM in Diets, Obesity Medications, Obesity. | Permalink
|
0 comments